Drug Profile
Research programme: anti-Ebola therapies - RedHill Biopharma
Alternative Names: Ebola Therapy - RedHill BiopharmaLatest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator RedHill Biopharma
- Developer National Institute of Allergy and Infectious Diseases; RedHill Biopharma
- Class Antivirals
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Ebola virus infections